Shenzhen Yiwei Medical Technology Co., Ltd. is a leader in precise diagnosis and treatment of brain diseases in China, and the first brain science artificial intelligence enterprise to focus on ultra early screening and precise diagnosis and treatment of brain diseases. Yiwei's core products focus on precise screening, diagnosis, and rehabilitation treatment of brain diseases such as Alzheimer's disease and developmental disorders in stroke children. It is the only digital product company in China that covers the entire process of brain disease diagnosis and treatment.

Medical science has now led the industry in completing NMPA, CE, and FDA certifications for multiple brain disease functional modules, especially in the field of AD diagnosis. It has successfully completed the world's first NMPA Class III registration certificate for Alzheimer's disease AI assisted diagnosis in a multicenter clinical trial, won the national high-tech enterprise qualification, and has obtained more than 70 invention patents and software copyrights. The product has been implemented and applied in more than 200 tertiary hospitals and physical examination institutions nationwide, and has engaged in strategic cooperation with multiple top medical institutions, such as Meinian Health, Beilu Pharmaceutical, Baoshi Hua Medical Group, Haier Yingkang, etc; Yiwei has taken the lead in creating a full process diagnosis and treatment platform in China that covers precise diagnosis, disease screening, brain health management, and digital rehabilitation treatment, forming the most clinical and practical closed-loop business model